Adjuvant Nivolumab or Ipilimumab + Nivolumab Determined By Pathological Response To A Single Dose Of Neoadjvuant Nivolumab
Latest Information Update: 07 Nov 2024
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
- Indications Malignant melanoma
- Focus Therapeutic Use
Most Recent Events
- 05 Nov 2024 Status changed from recruiting to active, no longer recruiting.
- 02 Sep 2020 Status changed from active, no longer recruiting to recruiting.
- 03 Apr 2020 Status changed from recruiting to active, no longer recruiting.